Strategies for isolating and enriching cancer stem cells: Well begun is half done

Stem Cells and Development

Volumn 22, Issue 16, 2013, Pages 2221-2239

  Duan, Jiang Jie ^a   Qiu, Wen ^a   Xu, Sen Lin ^a   Wang, Bin ^a   Ye, Xian Zong ^a   Ping, Yi Fang ^a   Zhang, Xia ^a   Bian, Xiu Wu ^a   Yu, Shi Cang ^a  

^a SOUTHWEST HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ALDEHYDE DEHYDROGENASE; BIOLOGICAL MARKER; CD133 ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; CD20 ANTIGEN; CD24 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CD47 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; GREEN FLUORESCENT PROTEIN; HERMES ANTIGEN; HISTONE DEMETHYLASE; JUMONJI AT RICH INTERACTIVE DOMAIN 1B PROTEIN; MICROSOMAL AMINOPEPTIDASE; NESTIN; OCTAMER TRANSCRIPTION FACTOR 4; PROTEASOME; REACTIVE OXYGEN METABOLITE; RED FLUORESCENT PROTEIN; STAGE SPECIFIC EMBRYO ANTIGEN 1; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ADULT STEM CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOFLUORESCENCE IMAGING; CANCER STEM CELL; CELL ADHESION; CELL DIVISION; CELL HYPOXIA; CELL INVASION; CELL ISOLATION; CELL RENEWAL; CELL SELECTION; CELL SUBPOPULATION; CELL SURFACE; CELL SUSPENSION; CYTOLOGY; CYTOTOXICITY; EMBRYONIC STEM CELL; ENHANCER REGION; ENRICHMENT CULTURE; ENZYME ACTIVITY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; MITOCHONDRIAL MEMBRANE POTENTIAL; MULTIPOTENT STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; SIDE POPULATION CELL;

EID: 84881184270     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2012.0613     Document Type: Review

References (214)

1. Marusyk A and K Polyak. (2010). Tumor heterogeneity: Causes and consequences. Biochim Biophys Acta 1805:105-117
2. Pine SR, BM Ryan, L Varticovski, AI Robles and CC Harris. (2010). Microenvironmental modulation of asymmetric cell division in human lung cancer cells. ProcNatl Acad Sci U S A 107:2195-2200
3. Ali AS, A Ahmad, S Ali, B Bao, PA Philip and FH Sarkar. (2013). The role of cancer stem cells and miRNAs in defining the complexities of brain metastasis. J Cell Physiol 228:36-42
4. Liu G, X Yuan, Z Zeng, P Tunici, H Ng, IR Abdulkadir, L Lu, D Irvin, KL Black and JS Yu. (2006). Analysis of gene expression and chemoresistance of CD133 + cancer stem cells in glioblastoma. Mol Cancer 5:67
5. Bao S, Q Wu, RE McLendon, Y Hao, Q Shi, AB Hjelmeland, MW Dewhirst, DD Bigner and JN Rich. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756-760
6. Clarke MF. (2005). A self-renewal assay for cancer stem cells. Cancer Chemother Pharmacol 56 Suppl 1:64-68
7. Clarke MF, JE Dick, PB Dirks, CJ Eaves, CH Jamieson, DL Jones, J Visvader, IL Weissman and GM Wahl. (2006). Cancer stem cells -perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66:9339-9344
8. Lapidot T, C Sirard, J Vormoor, B Murdoch, T Hoang, J Caceres-Cortes, M Minden, B Paterson, MA Caligiuri and JE Dick. (1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367:645-648
9. Bonnet D and JE Dick. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730-737
10. Al-Hajj M, MS Wicha, A Benito-Hernandez, SJ Morrison and MF Clarke. (2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100:3983-3988
11. Wright MH, AM Calcagno, CD Salcido, MD Carlson, SV Ambudkar and L Varticovski. (2008). Brca1 breast tumors contain distinct CD44 + /CD24-And CD133 + cells with cancer stem cell characteristics. Breast Cancer Res 10:R10
12. Hwang-Verslues WW, WH Kuo, PH Chang, CC Pan, HH Wang, ST Tsai, YM Jeng, JY Shew, JT Kung, et al. (2009). Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One 4:e8377
13. Pece S, D Tosoni, S Confalonieri, G Mazzarol, M Vecchi, S Ronzoni, L Bernard, G Viale, PG Pelicci and PP Di Fiore. (2010). Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140:62-73
14. Cho RW, X Wang, M Diehn, K Shedden, GY Chen, G Sherlock, A Gurney, J Lewicki and MF Clarke. (2008). Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells 26:364-371
15. Meyer MJ, JM Fleming, AF Lin, SA Hussnain, E Ginsburg and BK Vonderhaar. (2010). CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptornegative breast cancer. Cancer Res 70:4624-4633
16. Singh SK, C Hawkins, ID Clarke, JA Squire, J Bayani, T Hide, RM Henkelman, MD Cusimano and PB Dirks. (2004). Identification of human brain tumour initiating cells. Nature 432:396-401
17. Son MJ, K Woolard, DH Nam, J Lee and HA Fine. (2009). SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 4:440-452
18. Ward RJ, L Lee, K Graham, T Satkunendran, K Yoshikawa, E Ling, L Harper, R Austin, E Nieuwenhuis, et al. (2009). Multipotent CD15 + cancer stem cells in patched-1-deficient mouse medulloblastoma. Cancer Res 69:4682-4690
19. Tchoghandjian A, N Baeza, C Colin, M Cayre, P Metellus, C Beclin, L Ouafik and D Figarella-Branger. (2010). A2B5 cells from human glioblastoma have cancer stem cell properties. Brain Pathol 20:211-221
20. Ogden AT, AE Waziri, RA Lochhead, D Fusco, K Lopez, JA Ellis, J Kang, M Assanah, GM McKhann, et al. (2008). Identification of A2B5 + CD133-Tumor-initiating cells in adult human gliomas. Neurosurgery 62:505-514; discussion 514-505
21. Mazzoleni S, LS Politi, M Pala, M Cominelli, A Franzin, L Sergi Sergi, A Falini, M De Palma, A Bulfone, PL Poliani and R Galli. (2010). Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Res 70:7500-7513
22. Collins AT, PA Berry, C Hyde, MJ Stower and NJ Maitland. (2005). Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946-10951
23. Miki J, B Furusato, H Li, Y Gu, H Takahashi, S Egawa, IA Sesterhenn, DG McLeod, S Srivastava and JS Rhim. (2007). Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 67:3153-3161
24. Prince ME, R Sivanandan, A Kaczorowski, GT Wolf, MJ Kaplan, P Dalerba, IL Weissman, MF Clarke and LE Ailles. (2007). Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 104:973-978
25. Takaishi S, T Okumura, S Tu, SS Wang, W Shibata, R Vigneshwaran, SA Gordon, Y Shimada and TC Wang. (2009). Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27:1006-1020
26. Levin TG, AE Powell, PS Davies, AD Silk, AD Dismuke, EC Anderson, JR Swain and MH Wong. (2010). Characterization of the intestinal cancer stem cell marker CD166 in the human and mouse gastrointestinal tract. Gastroenterology 139:2072-2082 e2075
27. Li C, DG Heidt, P Dalerba, CF Burant, L Zhang, V Adsay, M Wicha, MF Clarke and DM Simeone. (2007). Identification of pancreatic cancer stem cells. Cancer Res 67:1030-1037
28. Hermann PC, SL Huber, T Herrler, A Aicher, JW Ellwart, M Guba, CJ Bruns and C Heeschen. (2007). Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1:313-323
29. O'Brien CA, A Pollett, S Gallinger and JE Dick. (2007). A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106-110
30. Ricci-Vitiani L, DG Lombardi, E Pilozzi, M Biffoni, M Todaro, C Peschle and R De Maria. (2007). Identification and expansion of human colon-cancer-initiating cells. Nature 445:111-115
31. Dalerba P, SJ Dylla, IK Park, R Liu, X Wang, RW Cho, T Hoey, A Gurney, EH Huang, et al. (2007). Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 104:10158-10163
32. Schepers AG, HJ Snippert, DE Stange, M van den Born, JH van Es, M van de Wetering and H Clevers. (2012). Lineage tracing reveals Lgr5 + stem cell activity in mouse intestinal adenomas. Science 337:730-735
33. Majeti R, MP Chao, AA Alizadeh, WW Pang, S Jaiswal, KD Gibbs, Jr., N van Rooijen and IL Weissman. (2009). CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138:286-299
34. Willingham SB, JP Volkmer, AJ Gentles, D Sahoo, P Dalerba, SS Mitra, J Wang, H Contreras-Trujillo, R Martin, et al. (2012). The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A 109:6662-6667
35. Kim CF, EL Jackson, AE Woolfenden, S Lawrence, I Babar, S Vogel, D Crowley, RT Bronson and T Jacks. (2005). Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121:823-835
36. Eramo A, F Lotti, G Sette, E Pilozzi, M Biffoni, A Di Virgilio, C Conticello, L Ruco, C Peschle and R De Maria. (2008). Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15:504-514
37. Bertolini G, L Roz, P Perego, M Tortoreto, E Fontanella, L Gatti, G Pratesi, A Fabbri, F Andriani, et al. (2009). Highly tumorigenic lung cancer CD133 + cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 106:16281-16286
38. Zhang HZ, XG Lin, P Hua, M Wang, X Ao, LH Xiong, C Wu and JJ Guo. (2010). The study of the tumor stem cell properties of CD133 + CD44 + cells in the human lung adenocarcinoma cell line A549. Cell Mol Biol (Noisy-le-grand) 56 Suppl:OL1350-OL 1358
39. Zhang WC, N Shyh-Chang, H Yang, A Rai, S Umashankar, S Ma, BS Soh, LL Sun, BC Tai, et al. (2012). Glycine dec-Arboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 148:259-272
40. Fang D, TK Nguyen, K Leishear, R Finko, AN Kulp, S Hotz, PA Van Belle, X Xu, DE Elder and M Herlyn. (2005). A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65:9328-9337
41. Schatton T, GF Murphy, NY Frank, K Yamaura, AM Waaga-Gasser, M Gasser, Q Zhan, S Jordan, LM Duncan, et al. (2008). Identification of cells initiating human melanomas. Nature 451:345-349
42. Boiko AD, OV Razorenova, M van de Rijn, SM Swetter, DL Johnson, DP Ly, PD Butler, GP Yang, B Joshua, et al. (2010). Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 466:133-137
43. Monzani E, F Facchetti, E Galmozzi, E Corsini, A Benetti, C Cavazzin, A Gritti, A Piccinini, D Porro, et al. (2007). Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43:935-946
44. Curley MD, VA Therrien, CL Cummings, PA Sergent, CR Koulouris, AM Friel, DJ Roberts, MV Seiden, DT Scadden, BR Rueda and R Foster. (2009). CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 27:2875-2883
45. Suetsugu A, M Nagaki, H Aoki, T Motohashi, T Kunisada and H Moriwaki. (2006). Characterization of CD133 + hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 351:820-824
46. Yin S, J Li, C Hu, X Chen, M Yao, M Yan, G Jiang, C Ge, H Xie, et al. (2007). CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120:1444-1450
47. Ma S, KW Chan, L Hu, TK Lee, JY Wo, IO Ng, BJ Zheng and XY Guan. (2007). Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132:2542-2556
48. Haraguchi N, H Ishii, K Mimori, F Tanaka, M Ohkuma, HM Kim, H Akita, D Takiuchi, H Hatano, et al. (2010). CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 120:3326-3339
49. Tirino V, V Desiderio, R d'Aquino, F De Francesco, G Pirozzi, A Graziano, U Galderisi, C Cavaliere, A De Rosa, G Papaccio and A Giordano. (2008). Detection and characterization of CD133 + cancer stem cells in human solid tumours. PLoS One 3:e3469
50. Adhikari AS, N Agarwal, BM Wood, C Porretta, B Ruiz, RR Pochampally and T Iwakuma. (2010). CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res 70:4602-4612
51. Shi C, R Tian, M Wang, X Wang, J Jiang, Z Zhang, X Li, Z He, W Gong and R Qin. (2010). CD44 + CD133 + population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma. Cancer Biol Ther 10:1182-1190
52. Watanabe K, MJ Meyer, L Strizzi, JM Lee, M Gonzales, C Bianco, T Nagaoka, SS Farid, N Margaryan, et al. (2010). Cripto-1 is a cell surface marker for a tumorigenic, undifferentiated subpopulation in human embryonal carcinoma cells. Stem Cells 28:1303-1314
53. Mehrazma M, Z Madjd, E Kalantari, M Panahi, A Hendi and A Shariftabrizi. (2012). Expression of stem cell markers, CD133 and CD44, in pediatric solid tumors: A study using tissue microarray. Fetal Pediatr Pathol. [Epub ahead of print]; DOI: 10.3109/15513815.2012.701266
54. Kemper K, MR Sprick, M de Bree, A Scopelliti, L Vermeulen, M Hoek, J Zeilstra, ST Pals, H Mehmet, G Stassi and JP Medema. (2010). The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res 70:719-729
55. Beier D, P Hau, M Proescholdt, A Lohmeier, J Wischhusen, PJ Oefner, L Aigner, A Brawanski, U Bogdahn and CP Beier. (2007). CD133 (+) and CD133 (-) glioblastomaderived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67:4010-4015
56. Meng X, M Li, X Wang, Y Wang and D Ma. (2009). Both CD133 + and CD133-subpopulations of A549 and H446 cells contain cancer-initiating cells. Cancer Sci 100:1040-1046
57. Zheng X, G Shen, X Yang and W Liu. (2007). Most C6 cells are cancer stem cells: Evidence from clonal and population analyses. Cancer Res 67:3691-3697
58. Shmelkov SV, JM Butler, AT Hooper, A Hormigo, J Kushner, T Milde, R St Clair, M Baljevic, I White, et al. (2008). CD133 expression is not restricted to stem cells, and both CD133 + and CD133-metastatic colon cancer cells initiate tumors. J Clin Invest 118:2111-2120
59. Oh SY, HJ Kang, YS Kim, H Kim and YC Lim. (2012). CD44-negative cells in head and neck squamous carcinoma also have stem-cell like traits. Eur J Cancer
60. Karbanova J, E Missol-Kolka, AV Fonseca, C Lorra, P Janich, H Hollerova, J Jaszai, J Ehrmann, Z Kolar, et al. (2008). The stem cell marker CD133 (Prominin-1) is expressed in various human glandular epithelia. J Histochem Cytochem 56:977-993
61. Park SY, HE Lee, H Li, M Shipitsin, R Gelman and K Polyak. (2010). Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 16:876-887
62. Yang Z, Z Wang, Y Fan and Q Zheng. (2012). Expression of CD133 in SW620 colorectal cancer cells is modulated by the microenvironment. Oncol Lett 4:75-79
63. Gopisetty G, J Xu, D Sampath, H Colman and VK Puduvalli. (2012). Epigenetic regulation of CD133/PROM1 expression in glioma stem cells by Sp1/myc and promoter methylation. Oncogene. [Epub ahead of print]; DOI: 10.1038/onc.2012.331
64. Pellacani D, RJ Packer, FM Frame, EE Oldridge, PA Berry, MC Labarthe, MJ Stower, MS Simms, AT Collins and NJ Maitland. (2011). Regulation of the stem cell marker CD133 is independent of promoter hypermethylation in human epithelial differentiation and cancer. Mol Cancer 10:94
65. Reynolds BA and S Weiss. (1996). Clonal and population analyses demonstrate that an EGF-responsive mammalian embryonic CNS precursor is a stem cell. Dev Biol 175:1-13
66. Visvader JE and GJ Lindeman. (2008). Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 8:755-768
67. Zhang G, L Ma, YK Xie, XB Miao and C Jin. (2012). Esophageal cancer tumorspheres involve cancer stem-like populations with elevated aldehyde dehydrogenase enzymatic activity. Mol Med Report 6:519-524
68. Pollard SM, K Yoshikawa, ID Clarke, D Danovi, S Stricker, R Russell, J Bayani, R Head, M Lee, et al. (2009). Glioma stem cell lines expanded in adherent culture have tumorspecific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4:568-580
69. Woolard K and HA Fine. (2009). Glioma stem cells: Better flat than round. Cell Stem Cell 4:466-467
70. Pastrana E, V Silva-Vargas and F Doetsch. (2011). Eyes wide open: A critical review of sphere-formation as an assay for stem cells. Cell Stem Cell 8:486-498
71. Krishnamurthy S and JE Nor. (2012). Orosphere assay: A method for propagation of head and neck cancer stem cells. Head Neck. [Epub ahead of print]; DOI: 10.1002/ hed.23076
72. Yoshida A, LC Hsu and V Dave. (1992). Retinal oxidation activity and biological role of human cytosolic aldehyde dehydrogenase. Enzyme 46:239-244
73. Ginestier C, MH Hur, E Charafe-Jauffret, F Monville, J Dutcher, M Brown, J Jacquemier, P Viens, CG Kleer, et al. (2007). ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555-567
74. Pearce DJ, D Taussig, C Simpson, K Allen, AZ Rohatiner, TA Lister and D Bonnet. (2005). Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells 23:752-760
75. Hess DA, L Wirthlin, TP Craft, PE Herrbrich, SA Hohm, R Lahey, WC Eades, MH Creer and JA Nolta. (2006). Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-Term reconstituting human hematopoietic stem cells. Blood 107:2162-2169
76. Chute JP, GG Muramoto, J Whitesides, M Colvin, R Safi, NJ Chao and DP McDonnell. (2006). Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci U S A 103:11707-11712
77. Armstrong L, M Stojkovic, I Dimmick, S Ahmad, P Stojkovic, N Hole and M Lako. (2004). Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells 22:1142-1151
78. Hess DA, TP Craft, L Wirthlin, S Hohm, P Zhou, WC Eades, MH Creer, MS Sands and JA Nolta. (2008). Widespread nonhematopoietic tissue distribution by transplanted human progenitor cells with high aldehyde dehydrogenase activity. Stem Cells 26:611-620
79. Feldmann G, S Dhara, V Fendrich, D Bedja, R Beaty, M Mullendore, C Karikari, H Alvarez, C Iacobuzio-Donahue, et al. (2007). Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: A new paradigm for combination therapy in solid cancers. Cancer Res 67:2187-2196
80. Balicki D. (2007). Moving forward in human mammary stem cell biology and breast cancer prognostication using ALDH1. Cell Stem Cell 1:485-487
81. Charafe-Jauffret E, C Ginestier, F Iovino, C Tarpin, M Diebel, B Esterni, G Houvenaeghel, JM Extra, F Bertucci, et al. (2010). Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 16:45-55
82. Jiang F, Q Qiu, A Khanna, NW Todd, J Deepak, L Xing, H Wang, Z Liu, Y Su, SA Stass and RL Katz. (2009). Aldehyde dehydrogenase 1 is a tumor stem cell-Associated marker in lung cancer. Mol Cancer Res 7:330-338
83. Neumeister V and D Rimm. (2010). Is ALDH1 a good method for definition of breast cancer stem cells? Breast Cancer Res Treat 123:109-111
84. Alison MR, NJ Guppy, SM Lim and LJ Nicholson. (2010). Finding cancer stem cells: Are aldehyde dehydrogenases fit for purpose? J Pathol 222:335-344
85. Duarte S, A Loubat, D Momier, M Topi, H Faneca, MC Pedroso de Lima, GF Carle and V Pierrefite-Carle. (2012). Isolation of head and neck squamous carcinoma cancer stem-like cells in a syngeneic mouse model and analysis of hypoxia effect. Oncol Rep 28:1057-1062
86. Korkaya H, A Paulson, F Iovino and MS Wicha. (2008). HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27: 6120-6130
87. Vlashi E, K Kim, C Lagadec, LD Donna, JT McDonald, M Eghbali, JW Sayre, E Stefani, W McBride and F Pajonk. (2009). In vivo imaging, tracking, and targeting of cancer stem cells. J Natl Cancer Inst 101:350-359
88. Pan J, Q Zhang, Y Wang and M You. (2010). 26S proteasome activity is down-regulated in lung cancer stem-like cells propagated in vitro. PLoS One 5:e13298
89. Xiang Y, Z Zhu, G Han, X Ye, B Xu, Z Peng, Y Ma, Y Yu, H Lin, AP Chen and CD Chen. (2007). JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc Natl Acad Sci U S A 104:19226-19231
90. Roesch A, M Fukunaga-Kalabis, EC Schmidt, SE Zabierowski, PA Brafford, A Vultur, D Basu, P Gimotty, T Vogt and M Herlyn. (2010). A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141:583-594
91. Held M and M Bosenberg. (2010). A role for the JARID1B stem cell marker for continuous melanoma growth. Pigment Cell Melanoma Res 23:481-483
92. Radberger P, A Radberger, VJ Bykov, S Seregard and MA Economou. (2012). JARID1B protein expression and prognostic implications in uveal melanoma. Invest Ophthalmol Vis Sci 53:4442-4449
93. Quintana E, M Shackleton, MS Sabel, DR Fullen, TM Johnson and SJ Morrison. (2008). Efficient tumour formation by single human melanoma cells. Nature 456:593-598
94. Shackleton MJ, E Quintana, DR Fullen, MS Sabel and TM Johnson. (2009). Melanoma: Do we need a hatchet or a scalpel? Arch Dermatol 145:307-308
95. Quintana E, M Shackleton, HR Foster, DR Fullen, MS Sabel, TM Johnson and SJ Morrison. (2010). Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18:510-523
96. Smith J, E Ladi, M Mayer-Proschel and M Noble. (2000). Redox state is a central modulator of the balance between self-renewal and differentiation in a dividing glial precursor cell. Proc Natl Acad Sci U S A 97:10032-10037
97. Ito K, A Hirao, F Arai, S Matsuoka, K Takubo, I Hamaguchi, K Nomiyama, K Hosokawa, K Sakurada, et al. (2004). Regulation of oxidative stress by ATM is required for selfrenewal of haematopoietic stem cells. Nature 431:997-1002
98. Tsatmali M, EC Walcott and KL Crossin. (2005). Newborn neurons acquire high levels of reactive oxygen species and increased mitochondrial proteins upon differentiation from progenitors. Brain Res 1040:137-150
99. Ito K, A Hirao, F Arai, K Takubo, S Matsuoka, K Miyamoto, M Ohmura, K Naka, K Hosokawa, Y Ikeda and T Suda. (2006). Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med 12:446-451
100. Tothova Z, R Kollipara, BJ Huntly, BH Lee, DH Castrillon, DE Cullen, EP McDowell, S Lazo-Kallanian, IR Williams, et al. (2007). FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 128:325-339
101. Miyamoto K, KY Araki, K Naka, F Arai, K Takubo, S Yamazaki, S Matsuoka, T Miyamoto, K Ito, et al. (2007). Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 1:101-112
102. Chen C, Y Liu, R Liu, T Ikenoue, KL Guan, Y Liu and P Zheng. (2008). TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. J Exp Med 205:2397-2408
103. Armstrong L, K Tilgner, G Saretzki, SP Atkinson, M Stojkovic, R Moreno, S Przyborski and M Lako. (2010). Human induced pluripotent stem cell lines show stress defense mechanisms and mitochondrial regulation similar to those of human embryonic stem cells. Stem Cells 28:661-673
104. Diehn M, RW Cho, NA Lobo, T Kalisky, MJ Dorie, AN Kulp, D Qian, JS Lam, LE Ailles, et al. (2009). Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458:780-783
105. Ye XQ, Q Li, GH Wang, FF Sun, GJ Huang, XW Bian, SC Yu and GS Qian. (2011). Mitochondrial and energy metabolism-related properties as novel indicators of lung cancer stem cells. Int J Cancer 129:820-831
106. Ishimoto T, O Nagano, T Yae, M Tamada, T Motohara, H Oshima, M Oshima, T Ikeda, R Asaba, et al. (2011). CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 19:387-400
107. Nesti C, L Pasquali, F Vaglini, G Siciliano and L Murri. (2007). The role of mitochondria in stem cell biology. Biosci Rep 27:165-171
108. Bavister BD. (2006). The mitochondrial contribution to stem cell biology. Reprod Fertil Dev 18:829-838
109. Lonergan T, B Bavister and C Brenner. (2007). Mitochondria in stem cells. Mitochondrion 7:289-296
110. Parker GC, G Acsadi and CA Brenner. (2009). Mitochondria: Determinants of stem cell fate? Stem Cells Dev 18:803-806
111. Pietila M, S Lehtonen, M Narhi, IE Hassinen, HV Leskela, K Aranko, K Nordstrom, A Vepsalainen and P Lehenkari. (2010). Mitochondrial function determines the viability and osteogenic potency of human mesenchymal stem cells. Tissue Eng Part C Methods 16:435-445
112. Heerdt BG, MA Houston, AJ Wilson and LH Augenlicht. (2003). The intrinsic mitochondrial membrane potential (Deltapsim) is associated with steady-state mitochondrial activity and the extent to which colonic epithelial cells undergo butyrate-mediated growth arrest and apoptosis. Cancer Res 63:6311-6319
113. Heerdt BG, MA Houston and LH Augenlicht. (2005). The intrinsic mitochondrial membrane potential of colonic carcinoma cells is linked to the probability of tumor progression. Cancer Res 65:9861-9867
114. Heerdt BG, MA Houston and LH Augenlicht. (2006). Growth properties of colonic tumor cells are a function of the intrinsic mitochondrial membrane potential. Cancer Res 66:1591-1596
115. Ye XQ, GH Wang, GJ Huang, XW Bian, GS Qian and SC Yu. (2011). Heterogeneity of mitochondrial membrane potential: A novel tool to isolate and identify cancer stem cells from a tumor mass? Stem Cell Rev 7:153-160
116. Michelakis ED, G Sutendra, P Dromparis, L Webster, A Haromy, E Niven, C Maguire, TL Gammer, JR Mackey, et al. (2010). Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2:31-34
117. Wong DJ, H Liu, TW Ridky, D Cassarino, E Segal and HY Chang. (2008). Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2:333-344
118. Yang M, M Yan, R Zhang, J Li and Z Luo. (2011). Side population cells isolated from human osteosarcoma are enriched with tumor-initiating cells. Cancer Sci 102:1774-1781
119. Bourguignon LY, G Wong, C Earle and L Chen. (2012). Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem 287:32800-32824
120. Bai L and LR Rohrschneider. (2010). s-SHIP promoter expression marks activated stem cells in developing mouse mammary tissue. Genes Dev 24:1882-1892
121. Levings PP, SV McGarry, TP Currie, DM Nickerson, S McClellan, SC Ghivizzani, DA Steindler and CP Gibbs. (2009). Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma. Cancer Res 69:5648-5655
122. Zbinden M, A Duquet, A Lorente-Trigos, SN Ngwabyt, I Borges and A Ruiz i Altaba. (2010). NANOG regulates glioma stem cells and is essential in vivo acting in a crossfunctional network with GLI1 and p53. Embo J 29:2659-2674
123. Tamase A, T Muraguchi, K Naka, S Tanaka, M Kinoshita, T Hoshii, M Ohmura, H Shugo, T Ooshio, et al. (2009). Identification of tumor-initiating cells in a highly aggressive brain tumor using promoter activity of nucleostemin. Proc Natl Acad Sci U S A 106:17163-17168
124. Vermeulen L, EMF De Sousa, M van der Heijden, K Cameron, JH de Jong, T Borovski, JB Tuynman, M Todaro, C Merz, et al. (2010). Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 12:468-476
125. Wu F, J Zhang, P Wang, X Ye, K Jung, KM Bone, JD Pearson, RJ Ingham, TP McMullen, Y Ma and R Lai. (2012). Identification of two novel phenotypically distinct breast cancer cell subsets based on Sox2 transcription activity. Cell Signal 24:1989-1998
126. Maksakova IA and DL Mager. (2005). Transcriptional regulation of early transposon elements, an active family of mouse long terminal repeat retrotransposons. J Virol 79:13865-13874
127. Hotta A, AY Cheung, N Farra, K Vijayaragavan, CA Seguin, JS Draper, P Pasceri, IA Maksakova, DL Mager, et al. (2009). Isolation of human iPS cells using EOS lentiviral vectors to select for pluripotency. Nat Methods 6:370-376
128. Shan J, J Shen, L Liu, F Xia, C Xu, G Duan, Y Xu, Q Ma, Z Yang, et al. (2012). Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology 56:1004-1014
129. Teisanu RM, E Lagasse, JF Whitesides and BR Stripp. (2009). Prospective isolation of bronchiolar stem cells based upon immunophenotypic and autofluorescence characteristics. Stem Cells 27:612-622
130. Ezzat T, DK Dhar, M Malago and SW Olde Damink. (2012). Dynamic tracking of stem cells in an acute liver failure model. World J Gastroenterol 18:507-516
131. Tacke F and R Weiskirchen. (2012). Update on hepatic stellate cells: Pathogenic role in liver fibrosis and novel isolation techniques. Expert Rev Gastroenterol Hepatol 6:67-80
132. Clement V, D Marino, C Cudalbu, MF Hamou, V Mlynarik, N de Tribolet, PY Dietrich, R Gruetter, ME Hegi and I Radovanovic. (2010). Marker-independent identification of glioma-initiating cells. Nat Methods 7:224-228
133. Weiss L. (2000). Metastasis of cancer: A conceptual history from antiquity to the 1990s. Cancer Metastasis Rev 19:I-XI, 193-383
134. Locke M, M Heywood, S Fawell and IC Mackenzie. (2005). Retention of intrinsic stem cell hierarchies in carcinomaderived cell lines. Cancer Res 65:8944-8950
135. Harper LJ, K Piper, J Common, F Fortune and IC Mackenzie. (2007). Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma. J Oral Pathol Med 36:594-603
136. Li H, X Chen, T Calhoun-Davis, K Claypool and DG Tang. (2008). PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Res 68:1820-1825
137. Kuch V, C Schreiber, W Thiele, V Umansky and JP Sleeman. (2013). Tumor-initiating properties of breast cancer and melanoma cells in vivo are not invariably reflected by spheroid formation in vitro, but can be increased by long-Term culturing as adherent monolayers. Int J Cancer 132:E94-E105
138. Lim YC, SY Oh and H Kim. (2012). Cellular characteristics of head and neck cancer stem cells in type IV collagencoated adherent cultures. Exp Cell Res 318:1104-1111
139. Zhou ZH, YF Ping, SC Yu, L Yi, XH Yao, JH Chen, YH Cui and XW Bian. (2009). A novel approach to the identification and enrichment of cancer stem cells from a cultured human glioma cell line. Cancer Lett 281:92-99
140. Sun Y, S Pollard, L Conti, M Toselli, G Biella, G Parkin, L Willatt, A Falk, E Cattaneo and A Smith. (2008). Long-Term tripotent differentiation capacity of human neural stem (NS) cells in adherent culture. Mol Cell Neurosci 38:245-258
141. Lee J, S Kotliarova, Y Kotliarov, A Li, Q Su, NM Donin, S Pastorino, BW Purow, N Christopher, et al. (2006). Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9:391-403
142. Li A, J Walling, Y Kotliarov, A Center, ME Steed, SJ Ahn, M Rosenblum, T Mikkelsen, JC Zenklusen and HA Fine. (2008). Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol Cancer Res 6:21-30
143. Goodell MA, K Brose, G Paradis, AS Conner and RC Mulligan. (1996). Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183:1797-1806
144. Van den Broeck A, L Gremeaux, B Topal and H Vankelecom. (2012). Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine. BMC Cancer 12:354
145. Ho MM, AV Ng, S Lam and JY Hung. (2007). Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 67:4827-4833
146. Wang J, LP Guo, LZ Chen, YX Zeng and SH Lu. (2007). Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res 67:3716-3724
147. Kondo T, T Setoguchi and T Taga. (2004). Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci U S A 101:781-786
148. Patrawala L, T Calhoun, R Schneider-Broussard, J Zhou, K Claypool and DG Tang. (2005). Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2 + and ABCG2-cancer cells are similarly tumorigenic. Cancer Res 65:6207-6219
149. Hirschmann-Jax C, AE Foster, GG Wulf, JG Nuchtern, TW Jax, U Gobel, MA Goodell and MK Brenner. (2004). A distinct ''side population'' of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 101:14228-14233
150. Hadnagy A, L Gaboury, R Beaulieu and D Balicki. (2006). SP analysis may be used to identify cancer stem cell populations. Exp Cell Res 312:3701-3710
151. Hu L, C McArthur and RB Jaffe. (2010). Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer 102:1276-1283
152. Burkert J, WR Otto and NA Wright. (2008). Side populations of gastrointestinal cancers are not enriched in stem cells. J Pathol 214:564-573
153. Lichtenauer UD, I Shapiro, K Geiger, M Quinkler, M Fassnacht, R Nitschke, KD Ruckauer and F Beuschlein. (2008). Side population does not define stem cell-like cancer cells in the adrenocortical carcinoma cell line NCI h295R. Endocrinology 149:1314-1322
154. Zhang H, H Xi, A Cai, Q Xia, XX Wang, C Lu, Y Zhang, Z Song, H Wang, et al. (2013). Not all side population cells contain cancer stem-like cells in human gastric cancer cell lines. Dig Dis Sci 58:132-139
155. Wu T, JY Li and SX Lu. (2012). [Isolation and characterization of side population cells in human gastric cancer cell line BGC-823]. Zhonghua Zhong Liu Za Zhi 34:264-268
156. Salcido CD, A Larochelle, BJ Taylor, CE Dunbar and L Varticovski. (2010). Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer. Br J Cancer 102:1636-1644
157. Morrison SJ and J Kimble. (2006). Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 441:1068-1074
158. Lanzkron SM, MI Collector and SJ Sharkis. (1999). Hematopoietic stem cell tracking in vivo: A comparison of shortterm and long-Term repopulating cells. Blood 93:1916-1921
159. Cicalese A, G Bonizzi, CE Pasi, M Faretta, S Ronzoni, B Giulini, C Brisken, S Minucci, PP Di Fiore and PG Pelicci. (2009). The tumor suppressor p53 regulates polarity of selfrenewing divisions in mammary stem cells. Cell 138:1083-1095
160. Kusumbe AP and SA Bapat. (2009). Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res 69:9245-9253
161. Xue Z, H Yan, J Li, S Liang, X Cai, X Chen, Q Wu, L Gao, K Wu, Y Nie and D Fan. (2012). Identification of cancer stem cells in vincristine preconditioned SGC7901 gastric cancer cell line. J Cell Biochem 113:302-312
162. Xin HW, DM Hari, JE Mullinax, CM Ambe, T Koizumi, S Ray, AJ Anderson, GW Wiegand, SH Garfield, SS Thorgeirsson and I Avital. (2012). Tumor-initiating labelretaining cancer cells in human gastrointestinal cancers undergo asymmetric cell division. Stem Cells 30:591-598
163. Jiang QP and KT Yao. (2010). Isolation and detection of label-retaining cells in a nasopharyngeal carcinoma cell line. Chin J Cancer 29:572-574
164. Deleyrolle LP, MR Rohaus, JM Fortin, BA Reynolds and H Azari. (2012). Identification and isolation of slow-dividing cells in human glioblastoma using carboxy fluorescein succinimidyl ester (CFSE). J Vis Exp 62:pii: 3918
165. Deleyrolle LP, A Harding, K Cato, FA Siebzehnrubl, M Rahman, H Azari, S Olson, B Gabrielli, G Osborne, A Vescovi and BA Reynolds. (2011). Evidence for labelretaining tumour-initiating cells in human glioblastoma. Brain 134:1331-1343
166. Kamohara Y, N Haraguchi, K Mimori, F Tanaka, H Inoue,M Mori and T Kanematsu. (2008). The search for cancer stem cells in hepatocellular carcinoma. Surgery 144:119-124
167. Moore N and S Lyle. (2011). Quiescent, slow-cycling stem cell populations in cancer: A review of the evidence and discussion of significance. J Oncol 2011: Pii: 396076
168. Salmaggi A, A Boiardi, M Gelati, A Russo, C Calatozzolo, E Ciusani, FL Sciacca, A Ottolina, EA Parati, et al. (2006). Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia 54:850-860
169. van Stijn A, MA van der Pol, A Kok, PM Bontje, GM Roemen, RH Beelen, GJ Ossenkoppele and GJ Schuurhuis. (2003). Differences between the CD34 + and CD34-blast compartments in apoptosis resistance in acute myeloid leukemia. Haematologica 88:497-508
170. Dean M, T Fojo and S Bates. (2005). Tumour stem cells and drug resistance. Nat Rev Cancer 5:275-284
171. Eramo A, L Ricci-Vitiani, A Zeuner, R Pallini, F Lotti, G Sette, E Pilozzi, LM Larocca, C Peschle and R De Maria. (2006). Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 13:1238-1241
172. Ghods AJ, D Irvin, G Liu, X Yuan, IR Abdulkadir, P Tunici, B Konda, S Wachsmann-Hogiu, KL Black and JS Yu. (2007). Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells. Stem Cells 25:1645-1653
173. Wei C, W Guo-min and L Yu-jun. (2006). Apoptosis resistance can be used in screening the markers of cancer stem cells. Med Hypotheses 67:1381-1383
174. Yu F, H Yao, P Zhu, X Zhang, Q Pan, C Gong, Y Huang, X Hu, F Su, J Lieberman and E Song. (2007). let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131:1109-1123
175. Li HZ, TB Yi and ZY Wu. (2008). Suspension culture combined with chemotherapeutic agents for sorting of breast cancer stem cells. BMC Cancer 8:135
176. Park CH, DE Bergsagel and EA McCulloch. (1971). Mouse myeloma tumor stem cells: A primary cell culture assay. J Natl Cancer Inst 46:411-422
177. Singh A and J Settleman. (2010). EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene 29:4741-4751
178. Nakai E, K Park, T Yawata, T Chihara, A Kumazawa, H Nakabayashi and K Shimizu. (2009). Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma. Cancer Invest 27:901-908
179. Yajima T, H Ochiai, T Uchiyama, N Takano, T Shibahara and T Azuma. (2009). Resistance to cytotoxic chemotherapyinduced apoptosis in side population cells of human oral squamous cell carcinoma cell line Ho-1-N-1. Int J Oncol 35:273-280
180. Li Z and JN Rich. (2010). Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. Curr Top Microbiol Immunol 345:21-30
181. Hong SP, J Wen, S Bang, S Park and SY Song. (2009). CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer 125:2323-2331
182. Griguer CE, CR Oliva, E Gobin, P Marcorelles, DJ Benos, JR Lancaster, Jr. and GY Gillespie. (2008). CD133 is a marker of bioenergetic stress in human glioma. PLoS One 3:e3655
183. Chartrain M, J Riond, A Stennevin, I Vandenberghe, B Gomes, L Lamant, N Meyer, JE Gairin, N Guilbaud and JP Annereau. (2012). Melanoma chemotherapy leads to the selection of ABCB5-expressing cells. PLoS One 7:e36762
184. Ghisolfi L, AC Keates, X Hu, DK Lee and CJ Li. (2012). Ionizing radiation induces stemness in cancer cells. PLoS One 7:e43628
185. Tang QL, Y Liang, XB Xie, JQ Yin, CY Zou, ZQ Zhao, JN Shen and J Wang. (2011). Enrichment of osteosarcoma stem cells by chemotherapy. Chin J Cancer 30:426-432
186. Bleau AM, D Hambardzumyan, T Ozawa, EI Fomchenko, JT Huse, CW Brennan and EC Holland. (2009). PTEN/ PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4:226-235
187. Di Fiore R, A Santulli, RD Ferrante, M Giuliano, A De Blasio, C Messina, G Pirozzi, V Tirino, G Tesoriere and R Vento. (2009). Identification and expansion of human osteosarcomacancer-stem cells by long-Term 3-Aminobenzamide treatment. J Cell Physiol 219:301-313
188. Calcagno AM, CD Salcido, JP Gillet, CP Wu, JM Fostel, MD Mumau, MM Gottesman, L Varticovski and SV Ambudkar. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst 102:1637-1652
189. Yu SC, YF Ping, L Yi, ZH Zhou, JH Chen, XH Yao, L Gao, JM Wang and XW Bian. (2008). Isolation and characterization of cancer stem cells from a human glioblastoma cell line U87. Cancer Lett 265:124-134
190. Pajic M, A Kersbergen, F van Diepen, A Pfauth, J Jonkers, P Borst and S Rottenberg. (2010). Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo. Cell Cycle 9:3780-3791
191. Kim Y, Q Lin, PM Glazer and Z Yun. (2009). Hypoxic tumor microenvironment and cancer cell differentiation. Curr Mol Med 9:425-434
192. Heddleston JM, Z Li, RE McLendon, AB Hjelmeland and JN Rich. (2009). The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 8:3274-3284
193. Conley SJ, E Gheordunescu, P Kakarala, B Newman, H Korkaya, AN Heath, SG Clouthier and MS Wicha. (2012). Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A 109:2784-2789
194. Louie E, S Nik, JS Chen, M Schmidt, B Song, C Pacson, XF Chen, S Park, J Ju and EI Chen. (2010). Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation. Breast Cancer Res 12:R94
195. Huang Z, L Cheng, OA Guryanova, Q Wu and S Bao. (2010). Cancer stem cells in glioblastoma -molecular signaling and therapeutic targeting. Protein Cell 1:638-655
196. Brabletz T, A Jung, S Spaderna, F Hlubek and T Kirchner. (2005). Opinion: Migrating cancer stem cells -An integrated concept of malignant tumour progression. Nat Rev Cancer 5:744-749
197. Sampieri K and R Fodde. (2012). Cancer stem cells and metastasis. Semin Cancer Biol 22:187-193
198. Asuthkar S, KK Velpula, C Chetty, B Gorantla and JS Rao. (2012). Epigenetic regulation of miRNA-211 by MMP-9 governs glioma cell apoptosis, chemosensitivity and radiosensitivity. Oncotarget 3:1439-1454
199. Velpula KK, AA Rehman, B Chelluboina, VR Dasari, CS Gondi, JS Rao and KK Veeravalli. (2012). Glioma stem cell invasion through regulation of the interconnected ERK, integrin alpha6 and N-cadherin signaling pathway. Cell Signal 24:2076-2084
200. Klarmann GJ, EM Hurt, LA Mathews, X Zhang, MA Duhagon, T Mistree, SB Thomas and WL Farrar. (2009). Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis 26:433-446
201. Zubeldia IG, AM Bleau, M Redrado, D Serrano, A Agliano, C Gil-Puig, F Vidal-Vanaclocha, J Lecanda and A Calvo. (2013). Epithelial to mesenchymal transition and cancer stem cell phenotypes leading to liver metastasis are abrogated by the novel TGFbeta1-Targeting peptides P17 and P144. Exp Cell Res 319:12-22
202. Hollier BG, AA Tinnirello, SJ Werden, KW Evans, JH Taube, TR Sarkar, N Sphyris, M Shariati, SV Kumar, et al. (2013). FOXC2 Expression Links Epithelial-Mesenchymal Transition and Stem Cell Properties in Breast Cancer. Cancer Res 6:1981-1992
203. Fan F, S Samuel, KW Evans, J Lu, L Xia, Y Zhou, E Sceusi, F Tozzi, XC Ye, SA Mani and LM Ellis. (2012). Overexpression of Snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells. Cancer Med 1:5-16
204. Yu SC and XW Bian. (2009). Enrichment of cancer stem cells based on heterogeneity of invasiveness. Stem Cell Rev 5:66-71
205. Walia V and RC Elble. (2010). Enrichment for breast cancer cells with stem/progenitor properties by differential adhesion. Stem Cells Dev 19:1175-1182
206. Reim F, Y Dombrowski, C Ritter, M Buttmann, S Hausler, M Ossadnik, M Krockenberger, D Beier, CP Beier, et al. (2009). Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: Selective escape of CD44high/CD24low/HER2low breast cancer stem cells. Cancer Res 69:8058-8066
207. Wolpert F, P Roth, K Lamszus, G Tabatabai,MWeller and G Eisele. (2012). HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells. J Neuroimmunol 250:27-34
208. Chen HC, AS Chou, YC Liu, CH Hsieh, CC Kang, ST Pang, CT Yeh, HP Liu and SK Liao. (2011). Induction of metastatic cancer stem cells from the NK/LAK-resistant floating, but not adherent, subset of the UP-LN1 carcinoma cell line by IFN-gamma. Lab Invest 91:1502-1513
209. Pietra G, C Manzini, M Vitale, M Balsamo, E Ognio, M Boitano, P Queirolo, L Moretta and MC Mingari. (2009). Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int Immunol 21:793-801
210. Tseng HC, A Arasteh, A Paranjpe, A Teruel, W Yang, A Behel, JA Alva, G Walter, C Head, et al. (2010). Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells. PLoS One 5:e11590
211. Jewett A, HC Tseng, A Arasteh, S Saadat, RE Christensen and NA Cacalano. (2012). Natural killer cells preferentially target cancer stem cells; role of monocytes in protection against NK cell mediated lysis of cancer stem cells. Curr Drug Deliv 9:5-16
212. Liu WH, X Wang, N You, KS Tao, T Wang, LJ Tang and KF Dou. (2012). Efficient enrichment of hepatic cancer stemlike cells from a primary rat HCC model via a density gradient centrifugation-centered method. PLoS One 7:e35720
213. Kuch V, C Schreiber, W Thiele, V Umansky and JP Sleeman. (2013). Tumor-initiating properties of breast cancer and melanoma cells in vivo are not invariably reflected by spheroid formation in vitro, but can be increased by longterm culturing as adherent monolayers. Int J Cancer 132:E94-E105
214. Tang DG. (2012). Understanding cancer stem cell heterogeneity and plasticity. Cell Res 22:457-472